Clinical trials: Hypopituitarism
Growth Hormone Disorder, Pituitary Dwarfism
An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)
This study is conducted in the United States of America (USA). The aim of this observational study is to collect data concerning the treatment outcomes and safety for children and adults who are prescribed Norditropin®.
- Conditions
- Growth Hormone Disorder, Pituitary Dwarfism, Hypopituitarism
- Trial name
- ANSWER (NCT01009905)
- Testing
- somatropin
- Where
- United States
- Volunteers
- 22,960 people
- Sponsor
- Novo Nordisk A/S
Hypopituitarism, Pituitary Insufficiency
A Prospective Observational Study of Effect of Somatropin on Growth Hormone Deficient Adults
The Hypopituitary Control and Complications Study "HypoCCS" is a prospective, open label, global, multicentre, observational study on routine clinical care of adults with growth hormone deficiency occurring either isolated or in…
- Conditions
- Hypopituitarism, Pituitary Insufficiency, Growth Hormone Deficiency, Adult
- Trial name
- HypoCCS (NCT01088399)
- Testing
- Somatropin (rDNA origin)
- Volunteers
- 10,673 people
- Sponsor
- Eli Lilly and Company
Growth Hormone Deficiency
VRS-317 in Adult Subjects With Growth Hormone Deficiency
The purpose of this research study is to determine the safety and tolerability of up to five doses of VRS-317 in Adult Growth Hormone Deficient patients.
- Trial name
- NCT01359488
- Testing
- VRS-317
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Versartis Inc.
Hypopituitarism
Comparison of Two Growth Hormone Dosing Methods in Adults With Growth Hormone Deficiency
This study tested whether a dose regimen of growth hormone based on body weight is equivalent or better than starting with a low dose and gradually increasing the dose according to individual patient needs.
- Trial name
- NCT00490191
- Testing
- Somatropin
- Where
- 26 sites in United States, France and 4 more
- Volunteers
- 387 people
- Sponsor
- Eli Lilly and Company